BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
IPO Year:
Exchange: NASDAQ
Website: biolifesolutions.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/4/2024 | $22.00 | Buy | Jefferies |
7/11/2023 | $29.00 | Buy | Craig Hallum |
4/25/2022 | $28.00 | Perform → Outperform | Oppenheimer |
10/19/2021 | $61.00 | Buy | B. Riley Securities |
10/15/2021 | $64.00 | Outperform | Cowen |
8/13/2021 | $50.00 → $60.00 | Overweight | Keybanc |
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
8-K/A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
DEFA14A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
DEF 14A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader bio
BOTHELL, Wash., July 25, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, lo
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash., May 29, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the introduction of the CryoCase, an addition to its CellSeal product line. "Particulates in drug product is a growing problem that we bel
Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 9, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three months ended March 31, 2024 and affirmed its revenue guidance for 2024.
BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log o
BOTHELL, Wash., April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling"). Roderick de Greef, Chairman and CEO, commented, "After a thorough and extensive process, we're pleased to have completed the divestiture of the Stirling freezer business. The sale is expected to
BOTHELL, Wash., March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences. TD Cowen 44th Annual Healthcare Conference (Boston, MA): March 5-6th1:1 Meeting on both daysFireside chat – Wednesday March 6th 9:15-9:45am
Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Feb. 29, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2023, and introduces 2024 revenue guidance.
BOTHELL, Wash., Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To acces
Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue. Roderick de Greef, Chairman and CEO, commented, "As we enter the new year, our team is fully committed to operational execution that positions BioLife for sustaine
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.
BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions. Mr. Goswami replaces Andrew Hinson, who has retired from the board. Mik
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company's chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen has over 40 years' experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen, an accredited public company director, currently serves as the CEO and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX). In addition, two other accredited public company directors and experienced life science execu
BOTHELL, Wash., April 6, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately. Mike Rice, BioLife CEO, commented, "We are very pleased to welcome Amy and Rachel as new independent directors to BioLife's board. They join BioLife at an exciting time. The addition of these directors complements our existing bo
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader bio
BOTHELL, Wash., July 25, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, lo
Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 9, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three months ended March 31, 2024 and affirmed its revenue guidance for 2024.
BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log o
Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Feb. 29, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2023, and introduces 2024 revenue guidance.
BOTHELL, Wash., Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To acces
Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the second quarter and six months of 2023 and updated guidance for the full year 2023. Management is also providing a first half 2023 financial profile of certain pro forma financial metrics excluding Stirling Ultracold (Stirling) and Custom Biogenic Systems (CBS) freeze
BOTHELL, Wash., July 27, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter financial results will be released after market close on Tuesday, August 8, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update. To access the webcast, log onto the
Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer Product Lines Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31,
BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update. To access the webcast, log onto the Inv
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00
Craig Hallum initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00
Oppenheimer upgraded BioLife Solutions from Perform to Outperform and set a new price target of $28.00
B. Riley Securities initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $61.00
Cowen resumed coverage of BioLife Solutions with a rating of Outperform and set a new price target of $64.00
Keybanc reiterated coverage of BioLife Solutions with a rating of Overweight and set a new price target of $60.00 from $50.00 previously
The Benchmark Company downgraded BioLife Solutions from Buy to Hold
Benchmark downgraded BioLife Solutions from Buy to Hold
Benchmark upgraded BioLife Solutions from Hold to Buy and set a new price target of $54.00
The Benchmark Company upgraded BioLife Solutions from Hold to Buy and set a new price target of $54.00
TD Cowen analyst Steven Mah maintains BioLife Solns (NASDAQ:BLFS) with a Buy and raises the price target from $20 to $26.
Benchmark analyst Robert Wasserman upgrades BioLife Solns (NASDAQ:BLFS) from Hold to Buy and announces $25 price target.
2024 Revenue GuidanceBioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR product line and do not include revenue from the freezer product line (GCI and CBS).Cell Processing platform: $66.0 million to $68.5 million, an increase of 0% to 4% compared with 2023. Compared with annualizing the second half of 2023 revenue run rate, the growth would be 17% to 22% Biostorage Services platform: $29.5 million to $31.5 million, an increase of 5% to 12% compared with 2023. This platform now includes the ThawSTAR automated thawi
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28) by 21.43 percent. The company reported quarterly sales of $16.20 million which missed the analyst consensus estimate of $26.01 million by 37.71 percent. This is a 57.03 percent decrease over sales of $37.70 million the same period last year.
The Nasdaq 100 closed lower by around 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Meta Platforms The Trade: Meta Platforms, Inc. (NASDAQ:META) Chief Legal Officer Jennifer Newstead sold a total of 585 sha
Jefferies analyst Matthew Stanton initiates coverage on BioLife Solns (NASDAQ:BLFS) with a Buy rating and announces Price Target of $22.